[{"id":"bd47dd42-9e42-4495-884c-94076f8c36c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02270372","created_at":"2021-01-18T10:40:37.901Z","updated_at":"2024-07-02T16:37:10.668Z","phase":"Phase 1b","brief_title":"Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer","source_id_and_acronym":"NCT02270372","lead_sponsor":"Cascadian Therapeutics Inc.","biomarkers":" MUC1","pipe":"","alterations":" ","tags":["MUC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e varlilumab (CDX 1127) • ONT-10"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 06/01/2016","study_completion_date":" 06/01/2016","last_update_posted":"2018-05-17"}]